The Architecture Decision Pharmacovigilance AI Cannot Defer

The Architecture Decision Pharmacovigilance AI Cannot Defer

Most pharmacovigilance automation debates focus on what the AI can catch: adverse event signals buried in call center transcripts, social media, or literature at volumes no human team can process manually. The harder question is where that processing happens, and regulated sponsors are running out of time to answer it as an afterthought.

Automated PV systems increasingly rely on multilingual natural language processing to triage safety data across markets, but data privacy and cross-jurisdictional compliance remain complex hurdles, with GDPR and national data localization laws complicating any unified, global cloud deployment. That is not a footnote. It is an architecture constraint that determines whether a PV AI system can be validated, audited, and defended under the frameworks now converging on it.

Two regulatory tracks are closing in simultaneously. Under the EU AI Act, the European AI Board and national authorities are already progressing with first formal supervisory and auditing checks on transparency obligations, with high-risk system enforcement still ahead. Separately, AI-enabled software as a medical device faces tightening requirements across major markets that developers must plan for as divergent, not harmonized, evidence expectations. A PV system built on a single centralized model, trained and hosted in one jurisdiction, will struggle to satisfy either track once auditors start asking where the data lived, who processed it, and under what legal basis.

The instinct in many safety organizations has been to treat this as a legal problem, solved after the fact with data processing agreements and contractual carve-outs. That approach worked when PV automation meant rule-based case triage. It does not hold for generative and NLP-driven systems that ingest raw multilingual source data and generate structured outputs that feed regulatory submissions. If the underlying architecture routes protected data through a jurisdiction that does not permit it, no amount of contractual paper fixes the model’s provenance problem after deployment.

This matters more, not less, given the compliance stack sponsors already carry. Life sciences companies operating AI-enabled devices in Europe are already managing a dual-certification framework spanning MDR, IVDR, and the AI Act. Adding a PV AI system with unresolved data residency exposure does not sit alongside that burden. It compounds it, because auditors reviewing AI Act conformity will increasingly expect data lineage documentation as a baseline artifact, not a negotiated exception.

The decision facing safety and compliance leaders is architectural, not legal: federated or regionally partitioned processing that keeps data within its jurisdiction of origin, versus a centralized model that trades speed and simplicity for a compliance liability that grows with every market added. Sponsors that make this call now, while system design is still flexible, will validate faster when EU AI Act supervisory checks expand beyond transparency provisions. Sponsors that defer it will be re-architecting live safety systems under audit pressure, which is the most expensive way to learn where your data actually lives.

---

Board record

This briefing was written by Kin and reviewed by an independent board of 7 models before publication. Ruling: CLEARED.

Seat	Reviewer	Finding
Chair · Editorial Judgment	Claude	cleared. The core argument—that data residency is an architectural constraint rather than a legal afterthought—is coherent and logically structured, but the piece overstates regulatory urgency (claiming sponso
Source & Claim Verification	Qwen · local	cleared. Most claims are well-supported with citations, but a few lines lack specific references, such as the discussion on the complexity of data privacy and cross-jurisdictional compliance.
Regulatory & Framework Fidelity	Mistral	cleared. The briefing accurately reflects key compliance requirements from ISO 42001, EU AI Act, and FDA/MDR/IVDR but lacks explicit mapping to specific clauses or technical controls.
Technical Accuracy	Llama	cleared. The article accurately reflects current regulatory challenges and trends in pharmacovigilance AI, particularly regarding data privacy and cross-jurisdictional compliance.
Bias, Balance & Hype Control	Gemini	cleared. The briefing effectively identifies and addresses potential counterarguments regarding legal vs. architectural solutions, and largely avoids vendor hype by focusing on regulatory constraints rather th
Novelty & Non-Duplication	Grok	held. The federated-vs-centralized PV architecture urgency is a competent synthesis of already-circulating GDPR, EU AI Act, and SaMD compliance themes from the cited wire, without a clearly original claim o
Validation	DeepSeek	cleared. The central claim that data residency is a critical architectural constraint for PV AI is strongly supported by cited regulatory developments and industry analysis.

Sources cited: 14. Validation challenges: 0. Review cost: about $0.04. Learn how these briefings are written and verified.